Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System

This study analyzed 76,580 cases from the FDA Adverse Event Reporting System to assess how different reporter types affect the detection of cancer therapy-induced alopecia signals. It found that reporter characteristics significantly influence signal detection, with patients often amplifying signals related to psychological harm and healthcare professionals (HCPs) focusing on pharmacological plausibility. Docetaxel had the highest reporting odds ratio (ROR) among all reporters, but this decreased when restricted to HCP reports, where vismodegib showed the highest ROR. The study underscores the need for sex-sensitive counseling and monitoring, as 90% of reports involved female patients, and highlights the importance of integrating biological, psychosocial, and reporting perspectives for comprehensive alopecia management in oncology. Limitations include underreporting and lack of causal inference, suggesting future research should incorporate electronic health records and prospective studies.